In Managing Inflammation, Controlling White Blood Cell Flow may be Key
News Mar 27, 2013
To exit blood vessels and reach injured tissue, white blood cells must pass through a series of natural barriers. Some aspects of blood vessel architecture facilitate white cell migration to a greater degree than others, a means of self-regulation: Excessive migration can result in extreme inflammation, turning otherwise helpful white cells into agents of disease.
Research by Yale bioengineers reported March 26 in the journal PLOS ONE sheds new light on the roles of specific layers of vasculature, suggesting ways of controlling inflammation.
“By understanding the regulatory mechanisms within the vascular wall, we hope we can identify potential treatments to ensure or restore the balance between protection and destruction of tissues,” said Anjelica L. Gonzalez, assistant professor of biomedical engineering at Yale and principal investigator of the research.
The work focuses in particular on the function of a less permeable (and little studied, researchers said) layer of cells within the blood vessel wall known as the pericyte layer.
Using a composite microvascular model that incorporates both the inner and outer layers of blood vessels, Gonzalez and colleagues showed that the outer pericyte layer helps restrict the number of exiting white blood cells. This helps prevent excessive inflammation, they said. In contrast, the inner (endothelial) layer primes white blood cells for passage through the pericyte layer by transforming them into a more versatile cell subpopulation. A malfunctioning pericyte layer could be responsible for excessive inflammation, they said.
“The results suggest that any disease or disorder that can be termed inflammatory — including wound healing, tissue fibrosis and cancer metastasis — may be exacerbated because of a poor pericyte barrier,” said Gonzalez. “White blood cell-mediated inflammation, in particular, is related to the progression of many inflammatory disorders. These findings give us targets on the white blood cell that will allow us to develop therapeutics aimed at inhibiting their contribution to disease progression.”
The paper’s lead author is Chantal E. Ayres-Sander. Co-authors are Holly Lauridsen, Cheryl L. Maier, Parid Sava, and Jordan S. Pober.
The Hartwell Foundation, a Dubinsky New Initiatives Award, and the National Institutes of Health provided support for the research.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
7th International Conference on Bacteriology and Infectious Diseases
Jun 04 - Jun 05, 2018